NCT04494113
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy
StatusActive, Not Recruiting
PhaseEarly Phase 1
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 128 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Primary completion date changed from estimate of Nov 30, 2026 to Aug 14, 2026
- Study completion pushed from Nov 30, 2026 to Nov 12, 2027
- Notable Eligibility criteria shortened, about 20 words
- Secondary endpoints: details revised at 2 of 2 entries
- Study description revised
- Site details revised at 1 of 7 sites
- Notable Primary and study completion pushed from Jun 1, 2026 to Nov 30, 2026v125
- Notable Trial status: Suspended to Active, Not Recruitingv87
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Pharmacodynamic response
Timeframe: Up to 6-8 hours post-triapine infusion
Secondary (2)
Incidence of adverse events
Pharmacokinetic (PK) analysis
Arms and interventions
Treatment (triapine, surgical resection)Experimental
Patients receive triapine IV over 2 hours on day 1. Patients then undergo surgical resection and tissue collection 6-8 hours after the initiation of the triapine infusion. Patients also undergo biopsy and collection of blood samples on study.
Procedures: Biopsy Procedure, Biospecimen Collection, Resection
Drugs: Triapine
Sites
7 sites in 1 country